Recent data also indicate that inhibition of ERα by endocrine therapies such as tamoxifen may release NFκB from ERα-driven inhibition, possibly resulting in tamoxifen resistance and NFκB-driven tumor progression [11]. This evidence concerns the gene ESR1 and neoplasm.